DESTINY-Breast07: Patient Demographics (Results from Part 2/Module 7 [T-DXd in patients with active BMs] as of December 22, 2023 DCO)
Patient Disposition1
- In total, 35 patients were enrolled to this module, all patients received T-DXd monotherapy
- The median actual treatment duration was 13.6 months (range: 2.6-29.0)a
- The median duration of follow-up was 16.2 months
aTotal treatment duration, excluding dose delays
| n (%) | Module 7 T-DXd in patients with active BMs (N=35) |
| T-DXd ongoing | 17 (48.6) |
T-DXd discontinued Objective disease progression Withdrawn by patient AE Death | 18 (51.4) 10 (28.6) 4 (11.4) 2 (5.7) 2 (5.7) |
Module 7 T-DXd in patients with active BMs (N=35) | |
| Median age, years (range) | 49.0 (33.0-70.0) |
| Female, n (%) | 35 (100) |
Race, n (%) White Asian Black or African American |
12 (34.3) 2 (5.7) |
HER2 status, n (%) IHC 3+a IHC 2+/ISH+ |
1 (2.9) |
HR status, n (%) Positive Negative |
16 (45.7) |
ECOG performance status, n (%) 0 1 |
17 (48.6) |
| Received prior HER2-targeted therapy for mBC, n (%) | 18 (51.4) |
| No prior local treatment for BMs, n (%) | 24 (68.6) |
Abbreviations
AE = adverse event
;BM = brain metastases
;DCO = data cutoff
;ECOG = Eastern Cooperative Oncology Group
;HER2 = human epidermal growth factor receptor 2
;HR = hormone receptor
;IHC = immunohistochemistry
;ISH = in situ hybridization
;mBC = metastatic breast cancer
;T-DXd = trastuzumab deruxtecan
References
1. Anders CP, Loi S, Hamilton E, et al. Safety, tolerability, and antitumor activity of T-DXd in patients with HER2-positive mBC and active brain metastases in DESTINY-Breast07. Poster 185P. Presented at European Society for Medical Oncology-Breast Cancer (ESMO-BC) Annual Meeting; May 15-17, 2024; Berlin, Germany.
Please note that this content may contain some data and/or patient populations which are considered off-label in your country. Providing this information does not constitute any recommendation for use. AstraZeneca is providing this material as an information service and professional courtesy.
To help us improve our content for health care professionals, please take this short survey.
Document ID: 325e86bc-2a1f-401a-b8d6-fa304896a85b
Last updated: 14-February-2023
©2023 AstraZeneca. All rights reserved.